Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2016, Article ID 7367232, 5 pages
http://dx.doi.org/10.1155/2016/7367232
Case Report

Rheumatoid Arthritis, Kartagener’s Syndrome, and Hyperprolactinemia: Who Started It?

King Faisal Specialist Hospital & Research Center, P.O. Box 40047, Jeddah 21499, Saudi Arabia

Received 24 October 2015; Accepted 3 January 2016

Academic Editor: Shigeko Inokuma

Copyright © 2016 Hussein Halabi and Israa Mulla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Brentano, D. Kyburz, O. Schorr, R. Gay, and S. Gay, “The role of Toll-like receptor signalling in the pathogenesis of arthritis,” Cellular Immunology, vol. 233, no. 2, pp. 90–96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Zangara, “On a case of Kartagener syndrome with associated rheumatoid arthritis,” Reumatismo, vol. 12, pp. 290–295, 1960. View at Google Scholar · View at Scopus
  3. G. L. Mastaglia and P. Goatcher, “Rare association of rheumatoid arthritis and Kartagener’s syndrome: a common denominator?” Medical Journal of Australia, vol. 2, no. 7, article 400, 1980. View at Google Scholar · View at Scopus
  4. A. Beutler and S. H. Mackiewicz, “Association of rheumatoid arthritis with Kartagener’s syndrome in a patient with HLA-DR1-DR4-B27 haplotype,” Zeitschrift für Rheumatologie, vol. 51, no. 5, pp. 253–255, 1992. View at Google Scholar · View at Scopus
  5. W. Porawska, K. Swierkocki, A. Marszalek, and S. Mackiewicz, “An unusual case of Kartagener’s syndrome associated with rheumatoid arthritis,” Polskie Archiwum Medycyny Wewnętrznej, vol. 96, no. 6, pp. 577–580, 1996. View at Google Scholar
  6. Y. Kawasaki, J. Suzuki, T. Sike et al., “Bucillamine-induced nephropathy in a child with juvenile rheumatoid arthritis and Kartagener’s syndrome,” Pediatrics International, vol. 42, no. 3, pp. 316–318, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Riente, P. Fadda, M. Mazzantini, S. Frigelli, B. Fattori, and E. Neri, “Kartagener’s syndrome and rheumatoid arthritis: an unusual association,” Clinical Rheumatology, vol. 20, no. 4, pp. 282–284, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Younes, I. Béjia, S. Zrour-Hassen, M. Touzi, and N. Bergaoui, “Rheumatoid arthritis and Kartagener syndrome: a rare combination,” Joint Bone Spine, vol. 73, no. 5, pp. 571–572, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. E. Rébora, J. A. Cuneo, J. Marcos, and J. C. Marcos, “Kartagener syndrome and rheumatoid arthritis,” Journal of Clinical Rheumatology, vol. 12, no. 1, pp. 26–29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Takasaki, S. Yamakage, S. Fukase, and T. Takahashi, “Kartagener’s syndrome and rheumatoid arthritis,” Internal Medicine, vol. 53, no. 3, pp. 269–274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Adań, J. Guzmán-Morales, M. G. Ledesma-Colunga et al., “Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis,” The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3902–3913, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Neidhart, R. E. Gay, and S. Gay, “Prolactin and prolactin-like polypeptides in rheumatoid arthritis,” Biomedicine and Pharmacotherapy, vol. 53, no. 5-6, pp. 218–222, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Ram, D. Blumberg, P. Newton, N. R. Anderson, and R. Gama, “Raised serum prolactin in rheumatoid arthritis: genuine or laboratory artefact?” Rheumatology, vol. 43, no. 10, pp. 1272–1274, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. T. D. Spector, “Rheumatoid arthritis,” Rheumatic Disease Clinics of North America, vol. 16, no. 3, pp. 513–537, 1990. View at Google Scholar · View at Scopus
  15. D. M. Lee and M. E. Weinblatt, “Rheumatoid arthritis,” The Lancet, vol. 358, no. 9285, pp. 903–911, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. J. S. Smolen, R. Landewé, F. C. Breedveld et al., “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update,” Annals of the Rheumatic Diseases, vol. 73, no. 3, pp. 492–509, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. F. E. Figueroa, F. Carrion, M. E. Martinez, S. Rivero, and I. Mamani, “Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis,” British Journal of Rheumatology, vol. 36, no. 9, pp. 1022–1023, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Salesi, S. Sadeghihaddadzavareh, P. Nasri, N. Namdarigharaghani, Z. Farajzadegan, and M. Hajalikhani, “The role of bromocriptine in the treatment of patients with active rheumatoid arthritis,” International Journal of Rheumatic Diseases, vol. 16, no. 6, pp. 662–666, 2013. View at Publisher · View at Google Scholar · View at Scopus